Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Kaken Gets Select-Asia Rights to Numab’s Multi-Specific Antibody
Kaken Pharmaceutical said on November 13 that it has signed a strategic licensing and co-development agreement with Swiss biotech Numab Therapeutics for NM81, a novel multi-specific antibody previously known as ND081. The Japanese drug maker exercised its option to acquire…
To read the full story
Related Article
- Kaken Snags Option Rights to Numab’s IBD Drug in Asia
November 18, 2024
- Kaken to Transfer Bispecific IP to J&J as US Giant Nabs Asset
May 30, 2024
- Kaken to Codevelop Novel Multi-Specific Antibody with Swiss Biotech
January 15, 2021
- Kaken, Numab Strike Deal for Multi-Specific Antibody in Inflammatory Disease
June 14, 2017
BUSINESS
- Terumo to Take US$610 Million Hit as CSL Plasma Supply Deal Ends
October 9, 2026
- TOPIX Shuffle Puts Mid-Tier Drug Makers, Wholesalers on Chopping Block
October 9, 2026
- Ono Gets Japan, Asia Rights to 3 IgG Degraders from Biohaven
October 9, 2026
- Datroway Snares TNBC Approval in China: Daiichi Sankyo
October 9, 2026
- Enhertu Gains Adjuvant Nod in China for HER2-Positive Breast Cancer
October 9, 2026
Japan’s plasma-derived product industry is approaching a turning point as the government prepares to step in with unprecedented support for…
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…